Genmab — November 2018

[peter12]

Ok jeg troede det var generelt ved transplantation (knoglemarv) og AB0 mismatch...

[E_L]

i wonder if we get to learn more about this, if it can be used more broadly with blood incompatibility in other circumstances .

[Bulder]

Exactly. In this specific case it was anemia after an allogeneic transplant. But PRCA is concidered an autoimmune decease, that can have many other causes. So maybe dara can play a role there.

[Parasitism]

Kom så - luk lige over 1.000

[Bulder]

desease

[E_L]

1 more try

[Bulder]

ok then
disease

[peter12]

Der blev lukket shorts i 1013

[PrivatInvestor84]

Looks like a close above 1.000

[GeorgeBest]

https://twitter.com/mtmdphd/status/1060290126834819072?s=21

[bibob]

God morgen. Og god weekend.

[polle1]

God morgen, god dag og god weekend

[Parasitism]

God morgen

[peter12]

Der er også nogen der bliver tørret i dag

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[E_L]

New trial: Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax https://clinicaltrials.gov/ct2/show/NCT03701321?term=NCT03701321&rank=1

[E_L]

it's a shame they don't yet start using SC in these new trials. Note though MRD as primary outcome.

[Sukkeralf]

they probably need sc dosing approved first

[bibob]

I think you are right Sukkeralf,!! - but when approved do you then think that they can change the study to use sc instead of iv. It looks like that sc has a better safety profile than iv !! - or am I wrong ??

[gentogen]

Tror ikke dette studie med Dara har været omtalt her (?): Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG). The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled